ITP
Iron Triangle Partners Portfolio holdings
AUM
$632M
This Quarter Return
+29.86%
1 Year Return
+26.53%
3 Year Return
+134.07%
5 Year Return
+312.1%
10 Year Return
–
AUM
$447M
AUM Growth
+$447M
(+16%)
Cap. Flow
-$15M
Cap. Flow
% of AUM
-3.36%
Top 10 Holdings %
Top 10 Hldgs %
59.6%
Holding
29
New
6
Increased
6
Reduced
8
Closed
4
Top Buys
| 1 |
Zimmer Biomet
ZBH
|
$20.4M |
| 2 |
Pacific Biosciences
PACB
|
$19.7M |
| 3 |
DaVita
DVA
|
$18.8M |
| 4 |
Elevance Health
ELV
|
$16.1M |
| 5 |
Vericel Corp
VCEL
|
$10.7M |
Top Sells
| 1 |
Baxter International
BAX
|
$28.4M |
| 2 |
Twist Bioscience
TWST
|
$24.3M |
| 3 |
McKesson
MCK
|
$13M |
| 4 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
$12.9M |
| 5 |
Hologic
HOLX
|
$9.45M |
Sector Composition
| 1 | Healthcare | 96.16% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Encompass Health
EHC
$12.3B
| $45.3M | 10.13% | 697,659 +147,659 | +27% | +$9.59M |
|
|
2
Zimmer Biomet
ZBH
$21B
| $30M | 6.69% | 220,000 +150,000 | +214% | +$20.4M |
|
3
Charles River Laboratories
CRL
$8.04B
| $29.4M | 6.58% | 130,000 | – | – |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $27.2M | 6.08% | 350,000 -86,127 | -20% | -$6.69M |
|
|
CTLT
5
DELISTED
CATALENT, INC.
CTLT
| $24M | 5.36% | 280,000 | – | – |
|
|
6
Hologic
HOLX
$14.9B
| $23.8M | 5.32% | 357,833 -142,167 | -28% | -$9.45M |
|
7
Boston Scientific
BSX
$156B
| $22.9M | 5.12% | 600,000 | – | – |
|
|
NVRO
8
DELISTED
NEVRO CORP.
NVRO
| $22.3M | 4.98% | 160,000 +9,515 | +6% | +$1.33M |
|
9
IQVIA
IQV
$32.4B
| $22.1M | 4.93% | 140,000 +2,423 | +2% | +$382K |
|
|
10
Pacific Biosciences
PACB
$393M
| $19.7M | 4.41% | +2,000,000 | New | +$19.7M |
|
|
11
DaVita
DVA
$9.85B
| $18.8M | 4.21% | +220,000 | New | +$18.8M |
|
12
Guardant Health
GH
$8.41B
| $18.6M | 4.15% | 166,000 +500 | +0.3% | +$55.9K |
|
13
Molina Healthcare
MOH
$9.8B
| $18.3M | 4.09% | 100,000 | – | – |
|
|
INOV
14
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $17.2M | 3.84% | 650,000 -83,053 | -11% | -$2.2M |
|
15
Surgery Partners
SGRY
$2.91B
| $16.4M | 3.67% | 750,000 +73,348 | +11% | +$1.61M |
|
|
16
Elevance Health
ELV
$71.8B
| $16.1M | 3.6% | +60,000 | New | +$16.1M |
|
|
AXNX
17
DELISTED
Axonics, Inc. Common Stock
AXNX
| $15.5M | 3.46% | 303,201 -44,390 | -13% | -$2.27M |
|
|
18
Vericel Corp
VCEL
$1.83B
| $10.7M | 2.4% | +580,000 | New | +$10.7M |
|
19
Bristol-Myers Squibb
BMY
$96B
| $9.04M | 2.02% | 150,000 -137,710 | -48% | -$8.3M |
|
20
Inspire Medical Systems
INSP
$2.77B
| $9.03M | 2.02% | 70,000 -46,054 | -40% | -$5.94M |
|
|
21
Twist Bioscience
TWST
$1.63B
| $7.6M | 1.7% | 100,000 -320,510 | -76% | -$24.3M |
|
22
Outset Medical
OM
$247M
| $7.5M | 1.68% | +150,000 | New | +$7.5M |
|
23
Envista
NVST
$3.52B
| $7.4M | 1.65% | 300,000 -200,000 | -40% | -$4.94M |
|
24
BioLife Solutions
BLFS
$1.2B
| $4.34M | 0.97% | +150,000 | New | +$4.34M |
|
25
Royalty Pharma
RPRX
$15.6B
| $4.21M | 0.94% | 100,000 | – | – |
|